{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:44:20Z","timestamp":1770482660200,"version":"3.49.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.carrev.2008.02.001","type":"journal-article","created":{"date-parts":[[2008,7,6]],"date-time":"2008-07-06T04:30:53Z","timestamp":1215318653000},"page":"166-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Role of urotensin II in atherosclerotic cardiovascular diseases"],"prefix":"10.1016","volume":"9","author":[{"given":"Rajbabu","family":"Pakala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2008.02.001_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/(SICI)1097-010X(19960601\/15)275:2\/3<226::AID-JEZ14>3.0.CO;2-H","article-title":"Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates","volume":"275","author":"Colton","year":"1996","journal-title":"J Exp Zool"},{"key":"10.1016\/j.carrev.2008.02.001_bib2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.bjp.0703690","article-title":"Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey","volume":"131","author":"Douglas","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/psc.590","article-title":"Structure\u2013activity relationship study on human urotensin II","volume":"11","author":"Guerrini","year":"2005","journal-title":"J Pept Sci"},{"key":"10.1016\/j.carrev.2008.02.001_bib4","doi-asserted-by":"crossref","first-page":"15803","DOI":"10.1073\/pnas.95.26.15803","article-title":"Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord","volume":"95","author":"Coulouarn","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.carrev.2008.02.001_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.104.065425","article-title":"Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro","volume":"310","author":"Russell","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.carrev.2008.02.001_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","article-title":"Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14","volume":"401","author":"Ames","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.carrev.2008.02.001_bib7","series-title":"The IUPHAR Compendium of Receptor Characterization and Classification","first-page":"365","article-title":"Urotensin receptors","author":"Douglas","year":"2000"},{"key":"10.1016\/j.carrev.2008.02.001_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjp.0704671","article-title":"Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey","volume":"136","author":"Elshourbagy","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.peptides.2004.03.030","article-title":"Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese","volume":"25","author":"Suzuki","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000015516","article-title":"Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization","volume":"88","author":"Protopopov","year":"2000","journal-title":"Cytogenet Cell Genet"},{"key":"10.1016\/j.carrev.2008.02.001_bib11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbrc.2003.09.102","article-title":"Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain","volume":"310","author":"Sugo","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.carrev.2008.02.001_bib12","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.peptides.2004.06.025","article-title":"Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain","volume":"25","author":"Mori","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.bjp.0703811","article-title":"Cardio-stimulant effects of urotensin-II in human heart in vitro","volume":"132","author":"Russel","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib14","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.bjp.0703513","article-title":"Human urotensin-II is an endothelium-dependent vasodilator small arteries","volume":"130","author":"Bottrill","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjp.0703601","article-title":"Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1","volume":"131","author":"Maguire","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjp.0705254","article-title":"Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice","volume":"139","author":"Behm","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00210-001-0503-0","article-title":"Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents","volume":"365","author":"Camarda","year":"2002","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.bjp.0704448","article-title":"Urotensin II evokes potent vasoconstriction in humans in vivo","volume":"135","author":"Bohm","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0008-6363(01)00485-0","article-title":"High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man","volume":"53","author":"Wilkinson","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2125.2002.t01-1-01704.x","article-title":"No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans","volume":"54","author":"Affolter","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib21","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/sj.bjp.0704051","article-title":"Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats","volume":"132","author":"Gardiner","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00004872-200301000-00026","article-title":"Central cardiovascular action of urotensin II in conscious rats","volume":"21","author":"Lin","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.carrev.2008.02.001_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.peptides.2005.07.012","article-title":"Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide","volume":"27","author":"Ishihata","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib24","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/01.CIR.0000121326.69153.98","article-title":"Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure","volume":"109","author":"Lim","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2008.02.001_bib25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.amjhyper.2005.03.748","article-title":"Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension","volume":"18","author":"Sondermeijer","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.carrev.2008.02.001_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1476-5381.1987.tb09000.x","article-title":"Complex effects of Gillichthys urotensin II on rat aortic strips","volume":"91","author":"Gibson","year":"1987","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0024-3205(01)01101-8","article-title":"Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition","volume":"69","author":"Gray","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.carrev.2008.02.001_bib28","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1016\/S0014-2999(00)00506-9","article-title":"Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries","volume":"402","author":"Katano","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib29","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/j.lfs.2005.11.002","article-title":"Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig","volume":"78","author":"Lacza","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.carrev.2008.02.001_bib30","doi-asserted-by":"crossref","first-page":"F792","DOI":"10.1152\/ajprenal.00342.2002","article-title":"Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney","volume":"285","author":"Zhang","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib31","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1097\/00005344-200036051-00051","article-title":"Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate","volume":"36","author":"Douglas","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib32","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/01.CIR.103.10.1378","article-title":"Effects of urotensin II in human arteries and veins of varying caliber","volume":"103","author":"Hillier","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2008.02.001_bib33","doi-asserted-by":"crossref","first-page":"H925","DOI":"10.1152\/ajpheart.2001.280.2.H925","article-title":"Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries","volume":"280","author":"Stirrat","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjp.0703314","article-title":"Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat","volume":"130","author":"MacLean","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2005.09.018","article-title":"Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats","volume":"523","author":"Ishihata","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00210-004-0873-1","article-title":"Urotensin-II: a novel systemic hypertensive factor in the cat","volume":"369","author":"Behm","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1291\/hypres.26.839","article-title":"Central cardiovascular action of urotensin II in spontaneously hypertensive rats","volume":"26","author":"Lin","year":"2003","journal-title":"Hypertens Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1161\/01.HYP.0000084633.85427.E6","article-title":"Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions","volume":"42","author":"Watson","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.carrev.2008.02.001_bib39","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/sj.ki.5000290","article-title":"Urotensin II and renal function in the rat","volume":"69","author":"Song","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.carrev.2008.02.001_bib40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/01.hjh.0000125452.28861.f1","article-title":"Plasma concentration of urotensin II is raised in hypertension","volume":"22","author":"Cheung","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.carrev.2008.02.001_bib41","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1213\/01.ANE.0000086723.97421.BC","article-title":"A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study","volume":"97","author":"Thompson","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.carrev.2008.02.001_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijcard.2005.07.008","article-title":"Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension","volume":"110","author":"Rdzanek","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib43","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/00004872-200112000-00011","article-title":"Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues","volume":"19","author":"Matsushita","year":"2001","journal-title":"J Hypertens."},{"key":"10.1016\/j.carrev.2008.02.001_bib44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/147323000603400306","article-title":"Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China","volume":"34","author":"Yi","year":"2006","journal-title":"J Int Med Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib45","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.peptides.2006.02.008","article-title":"Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance","volume":"27","author":"Ong","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/cs1040001","article-title":"Increased plasma urotensin II levels in patients with diabetes mellitus","volume":"104","author":"Totsune","year":"2003","journal-title":"Clin Sci"},{"key":"10.1016\/j.carrev.2008.02.001_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0016-6480(87)90251-6","article-title":"Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch","volume":"66","author":"Sheridan","year":"1987","journal-title":"en Comp Endocrinol"},{"key":"10.1016\/j.carrev.2008.02.001_bib48","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/hh1101.092034","article-title":"Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase","volume":"88","author":"Sauzeau","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib49","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/eje.0.1510803","article-title":"Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas","volume":"151","author":"Silvestre","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.carrev.2008.02.001_bib50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2001-15414","article-title":"Inhibition of insulin release by urotensin II\u2014a study on the perfused rat pancreas","volume":"33","author":"Silvestre","year":"2001","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib51","first-page":"876","article-title":"Confirmation of susceptibility gene loci on chromosome 1 in northern China Han families with type 2 diabetes","volume":"114","author":"Du","year":"2001","journal-title":"Chin Med J"},{"key":"10.1016\/j.carrev.2008.02.001_bib52","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2337\/diabetes.51.4.1247","article-title":"Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate loci on 7p and 11p","volume":"51","author":"Mori","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.carrev.2008.02.001_bib53","first-page":"223","article-title":"The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China","volume":"24","author":"Sun","year":"2002","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"10.1016\/j.carrev.2008.02.001_bib54","first-page":"1473","article-title":"The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population","volume":"82","author":"Zhu","year":"2002","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.carrev.2008.02.001_bib55","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s00125-003-1145-1","article-title":"Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects","volume":"46","author":"Wenyi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.carrev.2008.02.001_bib56","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.peptides.2005.03.043","article-title":"Urotensin II: evidence for cardiac, hepatic and renal production","volume":"26","author":"Charles","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib57","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002130100715","article-title":"Central effects of urotensin-II following ICV administration in rats","volume":"155","author":"Gartlon","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.carrev.2008.02.001_bib58","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0031-9384(01)00612-6","article-title":"The hypothalamus and the control of energy homeostasis: different circuits, different purposes","volume":"74","author":"Williams","year":"2001","journal-title":"Physiol Behav"},{"key":"10.1016\/j.carrev.2008.02.001_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00213-005-0140-2","article-title":"Behavioral effects of urotensin-II centrally administered in mice","volume":"183","author":"Do-Rego","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.carrev.2008.02.001_bib60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00210-004-0980-z","article-title":"Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators","volume":"370","author":"Johns","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1081\/RRS-120026972","article-title":"The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma","volume":"23","author":"Birker-Robaczewska","year":"2003","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib62","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.ATV.0000154279.98244.eb","article-title":"Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells","volume":"25","author":"Djordjevic","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.carrev.2008.02.001_bib63","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.amjhyper.2005.10.019","article-title":"Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease","volume":"19","author":"Mallamaci","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.carrev.2008.02.001_bib64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.regpep.2006.11.015","article-title":"The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts","volume":"140","author":"Dai","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.carrev.2008.02.001_bib65","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.peptides.2005.05.028","article-title":"Expression of urotensin-II in human coronary atherosclerosis","volume":"26","author":"Hassan","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2004.03.023","article-title":"Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta","volume":"176","author":"Bousette","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.carrev.2008.02.001_bib67","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.amjhyper.2006.08.001","article-title":"Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension","volume":"20","author":"Suguro","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.carrev.2008.02.001_bib68","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.peptides.2005.08.028","article-title":"Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout","volume":"27","author":"Wang","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib69","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.yjmcc.2005.07.002","article-title":"A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker","volume":"39","author":"Rakowski","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib70","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1291\/hypres.29.821","article-title":"Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide","volume":"29","author":"Watanabe","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/hc2601.092848","article-title":"Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells","volume":"104","author":"Watanabe","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2008.02.001_bib72","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/00004872-200112000-00012","article-title":"Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation","volume":"19","author":"Watanabe","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.carrev.2008.02.001_bib73","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2005.10.044","article-title":"Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells","volume":"188","author":"Shi","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.carrev.2008.02.001_bib74","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.HYP.0000184226.99196.b5","article-title":"Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages","volume":"46","author":"Watanabe","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.carrev.2008.02.001_bib75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijcard.2005.04.001","article-title":"Urotensin-II levels in acute coronary syndromes","volume":"108","author":"Joyal","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib76","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.peptides.2005.11.019","article-title":"Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers","volume":"27","author":"Gruson","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib77","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/01.CIR.0000044388.19119.02","article-title":"Plasma urotensin in human systolic heart failure","volume":"106","author":"Ng","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2008.02.001_bib78","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(02)09709-X","article-title":"Plasma urotensin II in heart failure","volume":"360","author":"Richards","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2008.02.001_bib79","doi-asserted-by":"crossref","first-page":"H1576","DOI":"10.1152\/ajpheart.00217.2003","article-title":"Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure","volume":"285","author":"Russell","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.regpep.2004.04.012","article-title":"The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease","volume":"121","author":"Heringlake","year":"2004","journal-title":"Regul Pept"},{"key":"10.1016\/j.carrev.2008.02.001_bib81","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.bjp.0703811","article-title":"Cardiostimulant effects of urotensin-II in human heart in vitro","volume":"132","author":"Russell","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib82","first-page":"2996","article-title":"ACC\/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary","volume":"104","author":"Hunt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2008.02.001_bib83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0014-5793(01)03015-0","article-title":"Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats","volume":"508","author":"Zou","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.carrev.2008.02.001_bib84","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.RES.0000084382.64418.BC","article-title":"Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy","volume":"93","author":"Tzanidis","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib85","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1210\/me.2003-0309","article-title":"Urotensin-II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases","volume":"18","author":"Onan","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.carrev.2008.02.001_bib86","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0140-6736(02)08831-1","article-title":"Congestive heart failure and expression of myocardial urotensin II","volume":"359","author":"Douglas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2008.02.001_bib87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijcard.2003.05.008","article-title":"Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy","volume":"94","author":"Lapp","year":"2004","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib88","first-page":"442","article-title":"Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion","volume":"55","author":"Zhou","year":"2003","journal-title":"Sheng Li Xue Bao"},{"key":"10.1016\/j.carrev.2008.02.001_bib89","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cardiores.2004.05.009","article-title":"Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart","volume":"63","author":"Russell","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.carrev.2008.02.001_bib90","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s380-002-8319-2","article-title":"Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium","volume":"16","author":"Zhang","year":"2002","journal-title":"Heart Vessels"},{"key":"10.1016\/j.carrev.2008.02.001_bib91","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijcard.2006.05.016","article-title":"Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans","volume":"117","author":"Khan","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib92","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/sj.ki.5000114","article-title":"Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease","volume":"69","author":"Zoccali","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.carrev.2008.02.001_bib93","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-2999(00)00672-5","article-title":"Human urotensin II mediates vasoconstriction via an increase in inositol phosphates","volume":"406","author":"Saetrum","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib94","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1254\/jphs.94.376","article-title":"Mechanism of human urotensin II-induced contraction in rat aorta","volume":"94","author":"Tasaki","year":"2004","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.carrev.2008.02.001_bib95","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0014-2999(02)01341-9","article-title":"Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists","volume":"438","author":"Rossowski","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib96","doi-asserted-by":"crossref","first-page":"H348","DOI":"10.1152\/ajpheart.00512.2006","article-title":"Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction","volume":"292","author":"Wang","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib97","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00210-006-0086-x","article-title":"Enhancement of vascular smooth muscle cell migration by urotensin II","volume":"3735","author":"Matsusaka","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib98","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0024-3205(02)02346-9","article-title":"Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling","volume":"72","author":"Tamura","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.carrev.2008.02.001_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-2999(88)90042-8","article-title":"Functional receptors for fish neuropeptide urotensin II in major rat arteries","volume":"149","author":"Itoh","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib100","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/S0196-9781(02)00266-8","article-title":"Structural requirements at the N-terminus of urotensin II octapeptides","volume":"23","author":"Coy","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib101","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/jm0111043","article-title":"Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure\u2013activity relationships and nuclear magnetic resonance studies on urotensin II","volume":"45","author":"Flohr","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.carrev.2008.02.001_bib102","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1016\/S0968-0896(02)00372-3","article-title":"Design, synthesis, conformational analysis and biological studies of urotensin-II lactam analogues","volume":"10","author":"Grieco","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.carrev.2008.02.001_bib103","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/1521-3773(20020816)41:16<2940::AID-ANIE2940>3.0.CO;2-M","article-title":"Structure\u2013function analysis of urotensin II and its use in the construction of a ligand-receptor working model","volume":"41","author":"Kinney","year":"2002","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.carrev.2008.02.001_bib104","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1021\/jm025549i","article-title":"A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge","volume":"45","author":"Grieco","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.carrev.2008.02.001_bib105","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1021\/jm025551+","article-title":"Discovery of the first nonpeptide agonist of the GPR14\/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954)","volume":"45","author":"Croston","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.carrev.2008.02.001_bib106","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bjp.0704887","article-title":"Pharmacological characterization of SB-710411 (Cpa-c[d-Cys-Pal-d-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist","volume":"137","author":"Behm","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bjp.0705251","article-title":"The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors","volume":"139","author":"Herold","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib108","series-title":"Urotensin-II receptor antagonists","author":"Dhanak","year":"2001"},{"key":"10.1016\/j.carrev.2008.02.001_bib109","series-title":"Urotensin-II receptor antagonists","author":"Dhanak","year":"2001"},{"key":"10.1016\/j.carrev.2008.02.001_bib110","series-title":"Vasoactive agents","author":"Tarui","year":"2001"},{"key":"10.1016\/j.carrev.2008.02.001_bib111","series-title":"Biphenyl compound","author":"Tarui","year":"2002"},{"key":"10.1016\/j.carrev.2008.02.001_bib112","series-title":"GPR14 antagonist","author":"Tarui","year":"2002"},{"key":"10.1016\/j.carrev.2008.02.001_bib113","series-title":"Preparation of 1,2,3,4-tetrahydroisoquinolinyl ureas and related derivatives as urotensin II receptor antagonists","author":"Aissaoui","year":"2002"},{"key":"10.1016\/j.carrev.2008.02.001_bib114","series-title":"reparation of N-(2-quinolinyl)propane-1,3-diamines as urotensin-II receptor antagonists","author":"Dhanak","year":"2002"},{"key":"10.1016\/j.carrev.2008.02.001_bib115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1124\/jpet.104.068320","article-title":"Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system","volume":"311","author":"Clozel","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.carrev.2008.02.001_bib116","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1471-4892(03)00012-2","article-title":"Human urotensin-II as a novel cardiovascular target: \u2018heart\u2019 of the matter or simply a fishy \u2018tail\u2019?","volume":"3","author":"Douglas","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.carrev.2008.02.001_bib117","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0705555","article-title":"Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta","volume":"140","author":"Patacchini","year":"2003","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.carrev.2008.02.001_bib118","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tips.2003.12.005","article-title":"From \u2018gills to pills\u2019: urotensin-II as a regulator of mammalian cardiorenal function","volume":"25","author":"Douglas","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.carrev.2008.02.001_bib119","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1124\/jpet.105.094821","article-title":"The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats","volume":"316","author":"Clozel","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.carrev.2008.02.001_bib120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.yjmcc.2006.05.008","article-title":".Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation","volume":"41","author":"Bousette","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.carrev.2008.02.001_bib121","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.peptides.2006.06.011","article-title":"Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease","volume":"27","author":"Bousette","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.carrev.2008.02.001_bib122","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11906-006-0026-7","article-title":"Urotensin-II and cardiovascular diseases","volume":"8","author":"Bousette","year":"2006","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.carrev.2008.02.001_bib123","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.clpt.2006.05.013","article-title":"Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients","volume":"80","author":"Sidharta","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.carrev.2008.02.001_bib124","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1522-1865(03)00182-3","article-title":"Radiation-induced atherosclerotic plaque progression in a hypercholesterolemic rabbit: a prospective vulnerable plaque model?","volume":"4","author":"Pakala","year":"2003","journal-title":"Cardiovasc Radiat Med."},{"key":"10.1016\/j.carrev.2008.02.001_bib125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.fjc.0000249891.40714.2a","article-title":"Peroxisome proliferator-activated receptor g ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit","volume":"48","author":"Pakala","year":"2006","journal-title":"J Cardio Vasc Pharmacol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838908000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838908000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:06:04Z","timestamp":1761559564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838908000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S1553838908000080"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2008.02.001","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of urotensin II in atherosclerotic cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2008.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}